MILLS ROBERT S 4
4 · TFF Pharmaceuticals, Inc. · Filed Feb 12, 2021
Insider Transaction Report
Form 4
MILLS ROBERT S
Director
Transactions
- Exercise/Conversion
Common Stock
2021-02-10$2.50/sh+700$1,750→ 16,680 total - Sale
Common Stock
2021-02-10$20.16/sh−700$14,112→ 15,980 total - Exercise/Conversion
Stock Options (Right to Buy)
2021-02-10−700→ 151,319 totalExercise: $2.50From: 2019-09-26Exp: 2028-09-26→ Common Stock (700 underlying)
Footnotes (3)
- [F1]The transactions reported by this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020.
- [F2]The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.
- [F3]36,005 shares of common stock vested on September 26, 2019 and the remainder of the shares vested at an approximate rate of 9,001 every three months thereafter.